CAS: 118-23-0; Bromazine

上下游产品

CAS号1808-12-4 2-[(4-溴苯基)苯基甲氧基...

📜4-苄氧基苯甲酸置于乙酰溴体系中,用 5,5-Dimethyl-1,3-Cyclohexadiene,苯 用作溶剂,化学反应 35.0H,反应生成溴苯海明
参考文献:苯海拉明的两种新的甲基和吗啉衍生物对大鼠的抗炎作用
标题:苯海拉明的两种新的甲基和吗啉衍生物对大鼠的抗炎作用
摘要:苯海拉明是乙醇胺类的第一代组胺h 1受体拮抗剂之一,具有许多药理特性,包括抗炎作用.在这项研究中,溴(II)和i的两个新的甲苯基衍生物(di [对甲苯基] [二甲基氨基乙氧基]甲烷(III)和(di [对甲苯基] [2-吗啉代乙氧基]甲烷(iv))合成.用福尔马林和组胺诱导的大鼠爪水肿评估了它们的急性和慢性抗炎活性.还测量了福尔马林和组胺引起的足爪水肿,二甲苯引起的耳部水肿以及在腹膜腔涂乙酸后的腹膜炎中的血管通透性,并与ii进行了比较.选择棉丸诱导的肉芽肿模型来诱导大鼠慢性炎症.新合成的苯海拉明类似物似乎可以有效减少急性炎症.结论是,新药的显着抗炎作用可能与其降低血管通透性机制或对h 1组胺受体的拮抗作用有关.
Doi:10.1007/s00044-011-9891-Y

专利信息

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

专利号:US-2005053642-A1
优先权日:2000-08-23
标题:Biocompatible materials
发明人：ULBRICHT MATHIAS; THOM VOLKMAR; JANKOVA KATJA; ALTANKOV GEORGE; JONSSON GUNNAR
摘要:The present invention teaches a novel approach of creating biocmpatible surfaces, said surfaces being capable of functionally interact with biological material. SAid biocompatible surfaces comrise at least two comonents, such as a hydrophobic substratum and a macromolecule of hydrophilic nature, which, in a cooperativity, form together the novel biocoompatible surfaces. The novel approach is ased on contacting said hydrophobic substratum with a laterally patterned monomolecular layer of said hydrophilic and flexible macromolecules, exhibiting a pronounced excluded volume. The htus formed two component surface is, in respect to polarity and morphology, a molecularly heterogeneous surface. Structural features of said macromolecular monolayer (as e.g. the layer thickness or its lateral density) are determined by: i) the structural features of the layer forming macromolecules (as e.g. their MW or their molecular architecture) and ii) the method of creating said monomolecular layer (as e.g. by physi- or chemisorbing, or by chemically binding said macromolecules). The structural features of the layer forming macromolecules(s) is in turn determined by synthesis. AMount and conformation and thus also biological activity of biological material (as e.g. polypeptides) which contact the novel biocompatible surface, is determined and maintained by the cooperative action of the underlying hydrophobic substratum and the macromolecular layer. In this way it becomes possible to maintain and control biological interactions between said contacted polypeptides and other biological compounds as e.g. cells, antibodies and the like. Consequently, the present invention aims to reduce and/or eliminate the deactivation and/or denaturation associated with the contacting of polypeptides and/or other biological material to a hydrophobic substratum surface.